Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sudarshan Pharma Industries Ltd, a micro-cap player in the specialty chemicals sector, has reported a flat financial performance for the quarter ended June 2026, marking a notable shift from its previously positive growth trajectory. Despite robust sales and profit growth over the last six months, rising interest expenses and margin pressures have weighed on the company’s overall financial health, prompting a downgrade in its Mojo Grade from Buy to Hold.

Sudarshan Pharma Industries Ltd, a micro-cap player in the Specialty Chemicals sector, has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Despite mixed signals from key indicators such as MACD and RSI, the stock’s recent price action and moving averages suggest a cautiously optimistic outlook for investors.

Sudarshan Pharma Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 August 2026, providing investors with the latest insights into its performance and outlook.

Sudarshan Pharma Industries Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent 5.00% decline in the stock price to ₹32.30, the company’s longer-term returns remain robust, though technical indicators present a mixed picture that warrants close attention from investors.

Sudarshan Pharma Industries Ltd, a micro-cap player in the Specialty Chemicals sector, has seen its investment rating downgraded from Buy to Hold as of 30 July 2026. This adjustment reflects a nuanced shift across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to demonstrate robust long-term growth and healthy financial performance, recent technical indicators and valuation metrics have moderated investor enthusiasm, prompting a more cautious stance.

Sudarshan Pharma Industries Ltd, a micro-cap player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, reflecting a transition from a bullish to a mildly bullish trend. Despite a 4.45% decline in the latest trading session, the stock’s broader technical indicators present a nuanced picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators.

Sudarshan Pharma Industries Ltd is rated Buy by MarketsMOJO, with this rating last updated on 07 July 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 30 July 2026, providing investors with the latest insights into the company’s performance and outlook.

With a decisive surge to Rs 42.16 on 21 Jul 2026, Sudarshan Pharma Industries Ltd has reached a fresh 52-week high, closing just 0.38% shy of this peak. This milestone caps a remarkable 47.55% rally over the past year, significantly outperforming the Sensex’s decline of 5.77% during the same period, underscoring the stock’s robust momentum amid a mixed broader market backdrop.

Sudarshan Pharma Industries Ltd is rated Buy by MarketsMOJO, with this rating last updated on 07 July 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 19 July 2026, providing investors with the latest insights into its fundamentals, returns, and overall outlook.

From a 52-week low of Rs 18.50 to a fresh high of Rs 42.16 on 15 Jul 2026, Sudarshan Pharma Industries Ltd has surged 128% in the past year, significantly outperforming the Sensex which declined 6.06% over the same period. This remarkable rally is underpinned by a confluence of bullish technical indicators and sustained price momentum, marking a notable milestone for the specialty chemicals micro-cap.

With a decisive intraday surge to Rs 41.4 on 13 Jul 2026, Sudarshan Pharma Industries Ltd has reached a fresh 52-week high, marking a 39.11% gain over the past year and significantly outperforming the Sensex’s 5.87% decline during the same period.

Sudarshan Pharma Industries Ltd has been upgraded from a Hold to a Buy rating, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality assessments. The micro-cap specialty chemicals company has demonstrated robust operational growth, market-beating returns, and a bullish technical outlook, prompting this positive revision in its investment rating.

Sudarshan Pharma Industries Ltd has demonstrated a notable shift in price momentum, supported by a range of technical indicators signalling a bullish trend. The stock’s recent performance, combined with upgraded technical grades and a strong Mojo Score, suggests growing investor confidence in this micro-cap specialty chemicals company.

With a decisive break above Rs 40.9 on 7 Jul 2026, Sudarshan Pharma Industries Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This surge comes amid a backdrop of strong technical signals that have aligned to propel the stock well beyond its previous resistance levels.

Sudarshan Pharma Industries Ltd has experienced a nuanced shift in its technical momentum, transitioning from a bullish to a mildly bullish trend. Despite a modest day change of 0.10% to close at ₹39.53, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages. This article analyses these developments in detail, placing them in the context of the company’s recent performance and broader market trends.